|
|||||
|
|
||||||
Originally published as JCO Early Release 10.1200/JCO.2009.23.1597 on September 8 2009 © 2009 American Society of Clinical Oncology. Relationship Between Potentially Modifiable Lifestyle Factors and Risk of Second Primary Contralateral Breast Cancer Among Women Diagnosed With Estrogen Receptor–Positive Invasive Breast CancerFrom the Divisions of Public Health Sciences and Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA. Corresponding author: Christopher I. Li, MD, PhD, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M4-C308, PO Box 19024, Seattle, WA 98109-1024; e-mail: cili{at}fhcrc.org. Purpose An outcome of considerable concern among breast cancer survivors is the development of second primary breast cancer. However, evidence regarding how potentially modifiable lifestyle factors modulate second breast cancer risk is limited. We evaluated the relationships between obesity, alcohol consumption, and smoking on risk of second primary invasive contralateral breast cancer among breast cancer survivors. Methods Utilizing a population-based nested case-control study design, we enrolled 365 patients diagnosed with an estrogen receptor–positive (ER+) first primary invasive breast cancer and a second primary contralateral invasive breast cancer, and 726 matched controls diagnosed with only an ER+ first primary invasive breast cancer. Obesity, alcohol use, and smoking data were ascertained from medical record reviews and participant interviews. Using conditional logistic regression we evaluated associations between these three exposures and second primary contralateral breast cancer risk.
Results Obesity, consumption of Conclusion Our population-based study adds to the limited available literature and suggests that obesity, smoking, and alcohol consumption influence contralateral breast cancer risk, affording breast cancer survivors three means of potentially reducing this risk. See accompanying editorial on page 5301 Supported by Grant No. R01-CA097271 from the National Cancer Institute. The National Cancer Institute did not play a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Related Article
This article has been cited by other articles:
|
||||||||||||
|
|||||||||||
|
Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|